IP Library › Granted Patent US 9,353,353
Granted Patent B2
US 9,353,353 · App. 13/131,287 · Granted May 31, 2016

Virus-like particles (VLPs) prepared from chikungunya virus structural proteins

Inventors: Gary J. Nabel (Washington, DC); Wataru Akahata (Kensington, MD); Srinivas Rao (Columbia, MD)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
C12N7/00A61K39/12A61K2039/5258A61K2039/55566C12N2740/16043C12N2770/36123C12N2770/36134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,353,353
App. No.
13/131,287
Granted
May 31, 2016
Kind
B2
Abstract

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

Claims (9)

1. A virus-like particle (VLP) comprising one or more Chikungunya virus structural polypeptides, wherein the one or more virus structural proteins are from Chikungunya virus strain 37997, and wherein the VLP does not early genetic information encoding the VLP proteins.

2. The VLP of claim 1 , wherein the structural polypeptides are selected from the group consisting of capsid (C) and envelope proteins E3, E2, 6K and E1.

3. The VLP of claim 1 , wherein the VLP comprises envelope proteins E3, E2, 6K and E1.

4. The VLP of claim 1 , wherein the VLP comprises a polyprotein comprising C-E3-E2-6K-E1.

5. An immunogenic composition comprising an effective amount of a virus-like particle of claim 1 .

6. The immunogenic composition of claim 5 , further comprising an adjuvant.

7. The immunogenic composition of claim 5 , wherein the VLP induces antibodies against homologous or heterologous strains of Chikungunya.

8. The immunogenic composition of claim 6 , wherein the adjuvant is an immunostimulating agent.

9. The immunogenic composition of claim 6 , wherein the adjuvant is selected from the group consisting of Ribi, aluminum salts, muramyl peptides, bacterial cell wall components, and saponin adjuvants.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2011
From: NABEL, GARY J.; AKAHATA, WATARU; RAO, SRINIVAS S.
To: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 026990/0572 →
Continuity (3)
Provisional Application 61118206 · Nov 26, 2008
Provisional Application 61201118 · Dec 5, 2008
Related Publication 20120003266A1 · Jan 5, 2012